- Conditions
- Hepatitis D
- Interventions
- Peginterferon Alpha-2a
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 130
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Hepatitis C
- Interventions
- Viramidine, Ribavirin, pegylated interferon alfa-2a
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 53
- States / cities
- Tucson, Arizona • Fresno, California • Los Angeles, California + 42 more
- Conditions
- Hepatitis, Hepatitis C
- Interventions
- Filibuvir, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 30
- States / cities
- Anaheim, California • Coronado, California • La Jolla, California + 22 more
- Conditions
- Hairy Cell Leukemia
- Interventions
- Roferon-A
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sarcoma, Kaposi, HIV Infections
- Interventions
- Interferon alfa-2a, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1993
- U.S. locations
- 9
- States / cities
- Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 6 more
- Conditions
- HIV Infections
- Interventions
- Pegylated interferon alfa-2a
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 3
- States / cities
- Sacramento, California • Chicago, Illinois • Durham, North Carolina
- Conditions
- Solid Cancers
- Interventions
- Atezolizumab, Bevacizumab, Interferon alfa-2b, Ipilimumab, Obinutuzumab, PEG-interferon alfa-2a
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more
- Conditions
- Polycythemia Vera, Essential Thrombocythemia
- Interventions
- RG7388, Pegasys
- Drug
- Lead sponsor
- John Mascarenhas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • New York, New York • Winston-Salem, North Carolina
- Conditions
- Hepatitis C
- Interventions
- ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
- Conditions
- Memory Disorders, Alzheimer's Disease
- Interventions
- Aricept, IFN-alpha2A
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV Infections, Hepatitis C
- Interventions
- Efavirenz, Lamivudine, Lopinavir/ritonavir, Pegylated interferon alfa-2a, Ribavirin, Tenofovir disoproxil fumarate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2007
- U.S. locations
- 2
- States / cities
- New York, New York • Dallas, Texas
- Conditions
- Hepatitis C
- Interventions
- Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Matching Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Peginterferon alfa-2a with Ribavirin, Peginterferon alfa-2a
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sarcoma, Kaposi, HIV Infections
- Interventions
- Interferon alfa-2a, Zidovudine, Interferon alfa-n1
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1990
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hepatitis C, Chronic
- Interventions
- Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 41 more
- Conditions
- Hepatitis B, Chronic
- Interventions
- peginterferon alfa-2a [Pegasys]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 6
- States / cities
- San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
- Conditions
- Pancreatic Neoplasms
- Interventions
- Heckel Infrared Radiant Heat Device, cisplatin, gemcitabine, interferon-alpha, thermochemotherapy
- Device · Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection
- Interventions
- ABT-267, Pegylated interferon (pegIFN), Ribavirin (RBV), Placebo for ABT-267
- Drug · Other
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 7 more
- Conditions
- HIV Infection
- Interventions
- Panobinostat, Pegylated Interferon-alpha2a
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hepatitis C, Hepatitis
- Interventions
- Merimepodib, PEG-Interferon-alpha 2a (Pegasys®), Ribavirin (Copegus®)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 55 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV)
- Drug
- Lead sponsor
- Janssen Infectious Diseases BVBA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 14
- States / cities
- Coronado, California • Los Angeles, California • San Francisco, California + 11 more
- Conditions
- Lymphoma
- Interventions
- Interferon-2A, Adriamycin, Bleomycin, Velban, Dacarbazine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- recombinant interferon alfa
- Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2005
- U.S. locations
- 7
- States / cities
- Wichita, Kansas • New Orleans, Louisiana • Hackensack, New Jersey + 4 more
- Conditions
- Hepatitis C
- Interventions
- TMC435, Placebo, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV)
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 11
- States / cities
- Bakersfield, California • Aurora, Colorado • Jacksonville, Florida + 8 more